BioNTech founder Ugur Sahin and Mayfield’s Ursheet Parikh are coming to Disrupt [TechCrunch Blog]
BioNTech SE - American Depositary Shares (BNTX)
Company Research
Source: TechCrunch Blog
BioNTech founder Ugur Sahin and Mayfield’s Ursheet Parikh are coming to DisruptDarrell Etherington@etherington/It’s hard to argue that any technology company has had a greater impact in the past decade than BioNTech, the mRNA-based therapeutics pioneer behind the world’s most widely-used COVID-19 vaccine. Developed in record time in partnership with Pfizer, thanks to an existing partnership to work on immunization for the common flu, BioNTech’s mRNA inoculation is without a doubt one of the biggest medical innovations of the past century.BioNTech co-founder and CEO Ugur Sahin isn’t stopping there, of course: the company recently announced that it would be developing an mRNA-based vaccine targeting malaria, an illness that still kills more than 400,000 people per year. It also has treatments for a range of cancers in process in its development pipeline, and has announced plans to address HIV and tuberculosis with future candidates.This year atDisrupt 2021Sahin and Parikh are just two o
Show less
Read more
Impact Snapshot
Event Time:
BNTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BNTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BNTX alerts
High impacting BioNTech SE - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
BNTX
News
- BioNTech SE (NASDAQ: BNTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $107.00 price target on the stock.MarketBeat
- Fragmented Europe to make new bid for US-style capital market [Reuters]Reuters
- Pfizer wins pause on Moderna's COVID-19 patent lawsuit [Reuters]Reuters
- Crescendo Biologics presents preclinical data on lead clinical candidate CB307 and unveils its first ‘2 in 1' immune cell engager CB699 at AACR 2024 [Yahoo! Finance]Yahoo! Finance
- Ryvu Therapeutics Presents Preclinical Data on RVU120 and Synthetic Lethality Programs at the 2024 AACR Annual Meeting [Yahoo! Finance]Yahoo! Finance
BNTX
Earnings
- 3/20/24 - Miss
BNTX
Sec Filings
- 4/8/24 - Form 6-K
- 4/8/24 - Form 6-K
- 3/25/24 - Form 6-K
- BNTX's page on the SEC website